ArticleScience (New York, N.Y.)2021
Targeting the nucleotide salvage factor DNPH1 sensitizes
Open access · greenAbstract read
In one paragraph
Article in Science (New York, N.Y.), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 89 papers.
0numbers the graph read from it
0cells of the map it votes in
89citing papers in PubMed
8.7field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
89 citing papers in PubMed, 130 citations in OpenAlex.
- Metabolic immune checkpoints (MICs) in cancer: from molecular mechanisms to challenges and opportunities in clinical translation.Signal transduction and targeted therapy · 2026Review
- Replication stress in cancer: origins, consequences and therapeutic opportunities.Nature reviews. Cancer · 2026Review
- DNPH1 exerts context-dependent tumor-promoting and -repressing functions during melanoma development.The Journal of investigative dermatology · 2026Article
- TET2 loss triggers ssDNA gap accumulation and heightened PARP inhibitor sensitivity.Nature communications · 2026Article
- Article
- Potentially Functional Variants ofCancers · 2026Article
- Combination of Niraparib and Lapatinib for Ovarian Cancer Treatment.Cancer research and treatment · 2026Article
- Tilting the balance of life and death: navigating DNA replication stress in cancer therapy.Experimental & molecular medicine · 2026Review
- Distinct repair outcomes from single and convergent replication fork collapse.Nature structural & molecular biology · 2026Article
- LINE1 RNA demethylation sensitizes cancer cells to PARPi through global chromatin remodeling.Genome biology · 2026Article
- Cross-ancestry proteome-wide Mendelian randomization prioritizes 12 plasma protein candidates for breast cancer risk.medRxiv : the preprint server for health sciences · 2026Article
- A Single-Enzyme Activated CRISPR-Cas12a Nano System via Subtly Balanced dsDNA for Kinetic-Gated UDG Detection and Spatiotemporal Cellular Imaging.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Behavioral and psychological symptoms of dementia: insights from a multivariate and network-based brain proteome-wide study.medRxiv : the preprint server for health sciences · 2026Article
- Metabolic drivers of genome instability in cancer: mechanisms and therapeutic opportunities.Experimental hematology & oncology · 2026Review
- Promotion of breast cancer by the DNPH1 enzyme.iScience · 2026Article
- Metabolism of Epigenetic Ribonucleosides Leads to Nucleolar Stress and Cytotoxicity.ACS chemical biology · 2026Article
- Clinical application of PARP inhibitors and emerging strategies to overcome resistance: a pan-cancer perspective.Biomarker research · 2026Review
- Targeting de novo pyrimidine synthesis confers vulnerability to copper-mediated ATR inactivation in PARP inhibitor-resistant ovarian cancer.Nature communications · 2026Article
- Exploiting synthetic lethality in epithelial ovarian cancer: multi-dimensional approaches beyond DNA damage repair.Molecular cancer · 2026Review
- The expanding roles of homologous recombination proteins in genome stability.The EMBO journal · 2026Review
29 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
14 authors at 2 institutions in 2 countries.
Kasper FuggerThe Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK. stephen.west@crick.ac.uk kasper.fugger@crick.ac.uk.ORCID https://orcid.org/0000-0001-9811-3983
Ilirjana BajramiThe Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK.ORCID https://orcid.org/0000-0003-2617-2938
Mariana Silva Dos SantosThe Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK.ORCID https://orcid.org/0000-0003-2404-8490
Sarah Jane YoungThe Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK.ORCID https://orcid.org/0000-0002-9394-1023
Simone KunzelmannThe Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK.ORCID https://orcid.org/0000-0002-2678-0549
Geoff KellyMRC Biomedical NMR Centre, The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK.ORCID https://orcid.org/0000-0002-1149-0717
Graeme HewittThe Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK.
Harshil PatelThe Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK.ORCID https://orcid.org/0000-0003-2707-7940
Robert GoldstoneThe Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK.
Thomas CarellFaculty of Chemistry and Pharmacy, Ludwig-Maximilians-Universität München, Butenandtstrasse 5-13, Building F, 81377 Munich, Germany.ORCID https://orcid.org/0000-0001-7898-2831
Simon J BoultonThe Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK.ORCID https://orcid.org/0000-0001-6936-6834
James MacRaeThe Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK.ORCID https://orcid.org/0000-0002-1464-8583
Ian A TaylorThe Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK.ORCID https://orcid.org/0000-0002-6763-3852
Stephen C WestThe Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK. stephen.west@crick.ac.uk kasper.fugger@crick.ac.uk.ORCID https://orcid.org/0000-0001-8848-9418
The Francis Crick Institute · GBLudwig-Maximilians-Universität München · DE
Funding
Cancer Research UK 28990Wellcome Trust FC001212
Abstract
Mutations in the
Indexed as
Antineoplastic AgentsApoptosisCell Line, TumorCRISPR-Cas SystemsDeoxycytidine MonophosphateDeoxyuracil NucleotidesDNA Breaks, Double-StrandedDNA, NeoplasmDNA ReplicationDrug Resistance, NeoplasmGenes, BRCA1HumansHydrolysisN-Glycosyl HydrolasesPhthalazinesPiperazines5-hydroxymethyl-2'-deoxyuridine5-hydroxymethyldeoxycytidine monophosphateAntineoplastic AgentsDeoxycytidine MonophosphateDeoxyuracil NucleotidesDNA, NeoplasmDNPH1 protein, humanN-Glycosyl HydrolasesolaparibPhthalazinesPiperazinesPoly(ADP-ribose) Polymerase InhibitorsPoly(ADP-ribose) PolymerasesProto-Oncogene ProteinsSMUG1 protein, humanThymidineUracil-DNA Glycosidase
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.